Show Notes
N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive with the update released this week.
Share talk spoke with Nigel Theobald, covering the latest announcement and asking him about the market response to news being released by the company, current share price and how often do they have to update the markets?
Have you fully funded all current work streams in Q1/2 in 2022, yes we have more than sufficient funds to carry out the work planned, just a few of the topics raised in the podcast.
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
Listen On
Also Listen
-
Tooru CEO talks results and strategy with Zak Mir
Zak Mir talks to Scott Livingston, CEO of Tooru Plc (AIM: TOO), after the UK-ba -
Gaming Realms CEO talks results and strategy with Zak Mir
Zak Mir talks to Mark Segal, CEO of Gaming Realms (AIM: GMR), the developer and -
Zak Mir Speaks to MedPal AI CEO Jason Drummond
Zak Mir talks to Jason Drummond, CEO of Medpal (AIM: MPAL), as the AI-native di -
Zak Mir interviews Ajax Resources CEO Ippolito Cattaneo
Zak Mir talks to Ippolito Cattaneo, CEO of Ajax Resources, as the natural resou